Conference Reports for NATAP

Back

EASL - European Association for the Study of the Liver May 7-10, 2025 Amsterdam the Netherlands     Clinically meaningful change of pruritus numeric rating scale in adults with primary biliary cholangitis with moderate to severe pruritus - (06/03/25)   Psychometric evaluation of the pruritus numeric rating scale in patients with primary biliary cholangitis with moderate to severe pruritus - (06/03/25)   Pharmacokinetics, Safety, and Tolerability of Seladelpar in People With Renal Impairment - (06/03/25)   Evaluation of the Potential Impact of Seladelpar on the Pharmacokinetics of Midazolam, Tolbutamide, Simvastatin, Rosuvastatin, and Atorvastatin - (06/03/25)   Current hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus across Europe - (05/23/25)   EASL Clinical Practice Guidelines Hepatitis B - (05/21/25)   Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates - (05/21/25)   Viral kinetics and sequence analysis of a Phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184 - (05/21/25)   First-in-human pharmacokinetics and pharmacodynamics of oral small-molecule PD-L1 inhibitor AB-101 and correlation to preclinical models - (05/21/25)   Preliminary safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101, a small molecule PD-L1 inhibitor, in healthy and chronic hepatitis B (CHB) subjects - (05/21/25)   IM-PROVE I: Rapid loss followed by transient increases in HBV RNA in chronic hepatitis B subjects during treatment with imdusiran and pegylated interferon alfa-2a is associated with HBsAg seroclearance - (05/20/25)   IM-PROVE I: Characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran plus short courses of pegylated interferon alfa-2a (IFN) and discontinuation of nucleos(t)ide analogue (NA) therapy - (05/20/25)   Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB) - (05/20/25)   In Vitro Characterization of Elebsiran (VIR-2218), an Investigational siRNA Therapeutic Targeting Hepatitis B Virus - (05/20/25)   Pharmacokinetics of Bemnifosbuvir in Participants With Renal Impairment - (05/20/25)   No DDI Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide - (05/20/25)   Pharmacokinetics of Bemnifosbuvir in Participants with Hepatic Impairment - (05/20/25)   Efficacy and Safety of Bemnifosbuvir and Ruzasvir After 8 Weeks of Treatment in Patients With Chronic Hepatitis C Virus (HCV) Infection - (05/20/25)   Response-guided interferon add-on to bulevirtide treatment: updated real-world insights from the austrian hepatitis D cohort study - (05/20/25)   A marker of cccDNA transcription - hepatitis B core-related antigen (HBcrAg) - mimics HBV RNA decline during antiviral therapy with bulevirtide in chronic hepatitis delta (HDV) patients - (05/20/25)   Burden of hepatitis D virus infection in Italy: results from the HDV describe study - (05/19/25)   SOLSTICE Week 24 Subgroup Analysis: Impact of Baseline Viral Parameters and Cirrhosis Status on Virological and Biochemical Responses in Participants With Chronic Hepatitis Delta Virus Infection Treated With Tobevibart and Elebsiran - (05/19/25)   Quantification of plasma HDV RNA by three commercially available assays in untreated and Bulevirtide-treated real-life patients with CHD: Robogene 2.0 vs. Altostar vs. Eurobioplex EBX071 - (05/19/25)   Real-world evidence shows comparable Bulevirtide effectiveness in hepatitis D patients with and without cirrhosis: results from the prospective nationwide D-Shield multicenter study - (05/19/25)   Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis D - (05/19/25)   PREVALENCE OF STEATOTIC LIVER DISEASE IN PEOPLE LIVING WITH HIV AND HIGH PREVALENCE OF CARDIOVASCULAR RISK FACTORS - (05/19/25)   Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo - (05/19/25)   Exercise partly protects against semaglutide-induced muscle loss in obese LDLR-/-.Leiden mice - (05/19/25)   Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial - (05/19/25)   Efimosfermin Alfa Once-Monthly Treatment Improves Collagen Biomarker Profiles and Rapidly Induces Histological Fibrosis Regression in Subjects with MASH Stage F2-F3 Fibrosis in a 24-week Phase 2 Trial - (05/19/25)   EASL Wrap-Up Viral Hepatitis: HBV, HDV, HEV - (05/14/25)   Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Moderate Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function - (05/14/25)   Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension in 122 patients with compensated MASH cirrhosis - (05/14/25)   Use of non-invasive tests to diagnose and follow MASH with liver fibrosis patients treated with resmetirom - (05/14/25)   Virological Response and Safety of Combination Treatment with Bulevirtide and Pegylated Interferon in Chronic Hepatitis D Patients with Advanced Fibrosis/Cirrhosis: 48 Weeks Interim Results from SEE-D Trial - (05/13/25)   Healthcare resource utilisation and costs associated with hepatitis delta virus infection compared with hepatitis B virus monoinfection prior to death among adults in Spain - (05/13/25)   Patient Characteristics and Treatment Patterns Amongst Hepatitis Delta Patients: Results From a Real-World Survey in Europe - (05/13/25)   Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Severe Renal Impairment and in Matched Control Participants With Normal Renal Function - (05/13/25)   Patient Characteristics and Treatment Patterns Amongst Hepatitis Delta Patients: Results From a Real-World Survey in Europe - (05/13/25)   Patient-Reported Outcomes Measuring an Individual's Overall Self-Rated Health After Long-Term Treatment With Bulevirtide 2 mg for Chronic Hepatitis Delta in the Phase 3 MYR301 Trial - (05/13/25)   A comparative study on liver disease severity and comorbidity profile in patients with chronic hepatitis B virus infection and hepatitis B virus/hepatitis D virus co-infection: a Korean nationwide study - (05/13/25)   Paediatric Pharmacokinetic-Pharmacodynamic Extrapolation to Identify Suitable Bulevirtide Doses for Children and Adolescents With Chronic Hepatitis Delta - (05/13/25)   Sodium Taurocholate Cotransporting Polypeptide Intronic Polymorphism rs17556915 Had No Impact on Hepatitis Delta Virus RNA Levels and Bulevirtide Response in Patients Treated With Bulevirtide - (05/13/25)   Course and Clinical Outcomes of Chronic Hepatitis Delta: A Longitudinal Analysis of 565 Patients from the D-SOLVE Consortium and HDV1000 Database - (05/13/25)   OPTION 1 BLV Monotherapy: Current Evidence from Trials and Real-world Data - (05/13/25)   A cross-sectional, intrahepatic analysis of HBV and HDV markers in liver transplants of untreated and Bulevirtide-treated patients with chronic hepatitis Delta - (05/13/25)   Low risk of decompensation and HCC in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for up to 144 weeks: the retrospective multicenter european study (Save-D) - (05/13/25)   Virological outcomes in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 144 weeks: a subanalysis of the retrospective multicenter european study (Save-D) - (05/13/25)   HERACLIS_BLV_D: Increasing response rates during 2-year bulevirtide real-life therapy in chronic hepatitis D - (05/13/25)   Efruxifermin in Compensated Liver Cirrhosis Caused by MASH - (05/12/25)   Identifying Risk Factors Associated with MASH for People Living with HIV - (05/12/25)   Outcomes beyond 10 years in entecavir or tenofovir treated Caucasian chronic hepatitis B patients of the real-life PAGE-B cohort - (05/12/25)   Outcomes of 48 Weeks of Therapy and Subsequent 24-Week Post-Treatment Period With Tobevibart (VIR-3434) and Elebsiran (VIR-2218) With or Without Pegylated Interferon Alfa-2a in Chronic Hepatitis B Virus Infection: Findings From the MARCH Study - (05/12/25)   Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis with two years of treatment with elafibranor - (05/12/25)   Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis: Proteomic results from the ELATIVE® trial - (05/12/25)   Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis Previously Treated With Fibrates or Obeticholic Acid - (05/12/25)   Safety of Seladelpar in Primary Biliary Cholangitis Patients With Cirrhosis and Clinical Signs of Portal Hypertension: Data From the ENHANCE and RESPONSE Studies - (05/12/25)   Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis with two years of treatment with elafibranor - (05/12/25)   8 weeks of Glecaprevir/Pibrentasvir is highly effective in patients with genotype 3 hepatitis C related cirrhosis, irrespective of the presence of clinically significant portal hypertension - (05/12/25)   Leave no one behind: an examination of how the hepatitis C elimination programme in England is reducing healthcare inequalities - (05/12/25)   Direct measurement of incidence and prevalence of Hepatitis C infection using the gold-standard of prospective HCV re-testing of people at risk. A national needs assessment of people who inject drugs and of all people who use addiction services in England - (05/12/25)   Trends in the effect of direct acting antivirals on mortality in people diagnosed with hepatitis C in England using routine surveillance data - (05/12/25)   Complex multiple morbidity and social vulnerability among hep C patients with delays accessing care UK - (05/12/25)   Mortality benefits of a national program of supported, active care in the treatment of marginalised people with chronic HCV infection - (05/12/25)   Longterm clinical outcomes outcome in Chronic hepatitis C after direct acting antivirals : a Prospective study - (05/12/25)   Outcome in patients with liver cirrhosis and hepatocellular carcinoma : comparing MRI and ultrasound for HCC surveillance - (05/12/25)   Final Results of MYR301: A Randomised Phase 3 Study Evaluating the Efficacy and Safety of BLV Monotherapy for Chronic Hepatitis Delta - (05/12/25)   A Mathematical Viral Load Model Characterises the Exposure-Response Relationship Between Bulevirtide and Hepatitis Delta Virus and Identifies the Minimum Duration of On-Treatment Viral Load Monitoring Required for Accurate Prediction of Long-Term Virologic Response - (05/12/25)   Improvement in 3 Noninvasive Tests Through 144 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta With and Without Virologic Response - (05/12/25)   Achieving Undetectable HDV RNA at End of Therapy With Bulevirtide With or Without PegIFNα is Strongly Associated With Posttreatment Virologic Response in CHD - (05/12/25)   Predictors of Undetectable Hepatitis Delta Virus RNA at 48 Weeks After End of Treatment With Bulevirtide Monotherapy in the MYR301 Study - (05/12/25)   Identifying Risk Factors Associated with MASH for People Living with HIV - (05/09/25)   Association between sustained virological response and adverse liver-related outcomes in patients with decompensated HCV cirrhosis - (05/09/25)   Global Survey of Practice Patterns in the Management of HCV-related Fibrosis - (05/09/25)   Changes in Hepatitis C Virus Screening and Treatment Rates in Pregnant Individuals Before and After Implementation of Universal Screening Guidelines Compared to Hepatitis B Virus Screening During the Same Time Frame - (05/09/25)   Linerixibat significantly improves cholestatic pruritus in PBC: results of the pivotal Phase 3 GLISTEN trial - (05/08/25)   Seladelpar Treatment of Patients With Primary Biliary Cholangitis Improves the GLOBE Score and Predicts Improved Transplant-Free Survival - (05/08/25)   Change in Pruritus in Patients With Primary Biliary Cholangitis and Moderate to Severe Pruritus: A Pooled Analysis From the RESPONSE and ENHANCE Studies - (05/08/25)   Risk of Advanced Liver Disease Among Individuals With Chronic Hepatitis B Virus Infection With Low-Level Viraemia Compared to Individuals With No Evidence of Chronic Hepatitis B Virus Infection - (05/08/25)   Impact of Long-Term Oral Antiviral Treatment on Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B Who Are Hepatitis B e Antigen Positive Using the PAGED-B Score - (05/08/25)   Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved faster and higher rate of hepatitis B virus surface antigen seroclearance on elebsiran plus peginterferon-alfa: end of treatment data from ENSURE study - (05/08/25)   Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from ongoing phase 2, randomized, open-label ENSURE study - (05/08/25)   Up to 18 months' functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: B-Sure third report - (05/08/25)   Safety and pharmacokinetics of bepirovirsen, delivered subcutaneously by vial, or prefilled syringe fitted with a safety syringe device in healthy adult participants, and syringe device ease of use: A randomised Phase 1 trial - (05/08/25)   Up to 2 years' functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: B-Sure third report - (05/08/25)   Atherosclerotic cardiovascular disease risk in chronic hepatitis C patients with metabolic dysfunction-associated steatotic liver disease after viral eradication: a multi-center cohort study: MASLD impacts outcomes - (05/07/25)   Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study - (05/07/25)   Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan - (05/07/25)   Glecaprevir/pibrentasvir in chronic HCV: An integrated analysis of participants on concomitant opioids, antipsychotics and cardiovascular medications - (05/07/25)   The SVR10K Hepatitis C study: Final results show 98.9% SVR in 7,000 patients treated with SOF/VEL in Asia, Latin America, Middle East, Nordic and Southern Europe - (05/07/25)   Healthcare resource use (HCRU) and cost impact of potential drug-drug interactions (DDIs) among HCV patients receiving direct-acting antivirals (DAAs) concomitantly with antipsychotic drugs in the US - (05/07/25)   The impact of cardio-metabolic risk factors on liver-related diseases and mortality after hepatitis C virus eradication: insights from a multi-center taiwanese cohort....mortality & liver outcomes related to cardio-metabolic risk factors - (05/07/25)   Efficacy and Safety of Glecaprevir/Pibrentasvir in Acute HCV Participants With a History of Prior Infection(s) - (05/07/25)